aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Monday. Stock index futures ( SPX ) were mixed on Monday as tech recovered after a major selloff in the sector on Friday. Company Move Quantum Corp. ( QMCO ) -3.1% Chagee Holdings ( CHA ) -2.1% Novo Nordisk A/S ( NVO ) -1.1% AstraZeneca PLC ( AZN ) -0.8% Opus Genetics ( IRD ) -0.7% The Campb...
aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Monday. Stock index futures ( SPX ) were mixed on Monday as tech recovered after a major selloff in the sector on Friday. Company Move Quantum Corp. ( QMCO ) -3.1% Chagee Holdings ( CHA ) -2.1% Novo Nordisk A/S ( NVO ) -1.1% AstraZeneca PLC ( AZN ) -0.8% Opus Genetics ( IRD ) -0.7% The Campbell's Co. ( CPB ) -0.7% DexCom, Inc. ( DXCM ) -0.5% Click to enlarge More on markets Monthly Macro Monitor: Nothing To See Here A Critical Week For The Markets Ahead SpaceX, Like Other Big IPOs, Has Disappointed Buyers, I'm Passing At a glance: stocks gapping up premarket Stock index futures mixed as tech recovers after selloff
Carl Lokko/iStock via Getty Images Alvotech ( ALVO ) is a commercial-stage company focusing on developing and manufacturing biosimilar versions of medications after those reference products lose exclusivity. ALVO also relies on regional partners to handle market access wherever appropriate. Interestingly, its biosimilars are gaining global traction but are seemingly facing some approval delays in ...
Carl Lokko/iStock via Getty Images Alvotech ( ALVO ) is a commercial-stage company focusing on developing and manufacturing biosimilar versions of medications after those reference products lose exclusivity. ALVO also relies on regional partners to handle market access wherever appropriate. Interestingly, its biosimilars are gaining global traction but are seemingly facing some approval delays in the US due to manufacturing-site issues. The FDA issued a Form 483, which listed observations that I think ALVO should be able to address quickly. ALVO has also resubmitted its BLA for AVT05, a biosimilar to Johnson & Johnson’s ( JNJ ) Simponi, and AVT06, a biosimilar to Regeneron’s ( REGN ) Eylea. In my view, ALVO still has good prospects as long as its CMC setbacks resolve later this year, which is why I remain bullish on the stock. A Biosimilar Platform Worth Revisiting Alvotech is a commercial-stage biopharmaceutical company that develops biosimilar versions of major biologic drugs at a lower cost. The company was founded back in 2013, and it's currently headquartered in Reykjavik, Iceland. I previously covered ALVO last October, and since then, the stock has pulled back significantly. However, I believe their CMC bottleneck for biosimilars seems relatively fixable. As such, I felt it was worthwhile taking another look at this name. Source: Corporate Presentation. May 2026. As a quick recap, ALVO works with partners to bring its biosimilars to market. The company develops the drugs, but its partners handle sales in different regions. These partners include Teva ( TEVA ) in the US, STADA in parts of Europe, Fuji Pharma in Japan, and Advanz in Europe. ALVO also partners with Cipla in Australia and New Zealand, JAMP in Canada, and others in Latin America, the Middle East, and more. Commercial Momentum Meets FDA Friction With that in mind, since my last update, ALVO has made good commercial progress, and its approved products are selling well. ALVO’s revenues increased, par...
The first JD Mall in Hong Kong. Photo: VCG JD.com Inc. will open its first physical JD Mall home appliance store in Hong Kong later this month, marking an important step in the e-commerce giant’s expansion into international markets. The Wan Chai outlet, which is set to begin operation on June 18, is part of its broader plan to establish six to eight experience-focused JD Mall stores in the city’s...
The first JD Mall in Hong Kong. Photo: VCG JD.com Inc. will open its first physical JD Mall home appliance store in Hong Kong later this month, marking an important step in the e-commerce giant’s expansion into international markets. The Wan Chai outlet, which is set to begin operation on June 18, is part of its broader plan to establish six to eight experience-focused JD Mall stores in the city’s popular commercial districts like Sha Tin and Mong Kok over the next three years, the company said on Friday.
photo_Pawel/iStock via Getty Images Introduction For me, June is one of my favorite months of the year. Not only does it mark the official start to summer, but it's also a time when people are excited to get out and travel, relax, and enjoy the warmer weather. Personally, I enjoy taking small road trips and sitting by poolsides. With June getting off to a rocky start and stocks pulling back, I can...
photo_Pawel/iStock via Getty Images Introduction For me, June is one of my favorite months of the year. Not only does it mark the official start to summer, but it's also a time when people are excited to get out and travel, relax, and enjoy the warmer weather. Personally, I enjoy taking small road trips and sitting by poolsides. With June getting off to a rocky start and stocks pulling back, I can honestly say I'm even more excited this year. At the time of writing, the Dow Jones Index ( DJI ) is down more than 400 points, creating what I believe are attractive buying opportunities in several high-quality stocks. Going forward, I think we will likely see stocks remain volatile as uncertainty surrounding inflation and rate hikes continues to build. However, long-term, income-focused investors should stay disciplined and continue dollar-cost averaging into quality businesses with strong fundamentals. In this article, I discuss which two dividend growth stocks I'm currently buying and why I believe both offer compelling upside potential over the next 24 to 36 months. Things Could Get Worse Markets are currently reacting to higher oil prices as the U.S. and Iran trade strikes. While talks of a deal between the two sides remain uncertain, one thing is likely: inflation will remain persistent for longer now. The spike in oil & fuel prices resulted in CPI hitting 3.8% , the third highest level since 2021. US Inflation Calculator As the conflict continues, rate hike chances continue to climb. Currently, economists predict a 41.3% chance of the FED hiking rates a quarter point by the end of the year. This is almost identical to the chances of rates staying where they are, much different compared to the beginning of the year, where we were expected to see multiple rate cuts in 2026. CME FedWatch The question is: What will happen if the FED does hike rates? I, personally, think we will see a market sell-off. Whether brief or prolonged, it could be the start of the bear market ...
(RTTNews) - Sempra Infrastructure, a subsidiary of utility company, Sempra (SRE), Monday announced that it has appointed Bhavesh Patel as its incoming chief executive officer as he will assume this role upon the closing of a KKR-led consortium's acquisition of a majority ownershi
(RTTNews) - Sempra Infrastructure, a subsidiary of utility company, Sempra (SRE), Monday announced that it has appointed Bhavesh Patel as its incoming chief executive officer as he will assume this role upon the closing of a KKR-led consortium's acquisition of a majority ownershi
If you owned Sprott Junior Copper Miners ETF (NASDAQ:COPJ) on Friday morning, you watched it open near $45.37 and close at $40.37, an 11% single-day tumble on June 5, 2026. A $10,000 stake at Thursday’s close became roughly $8,900 by Friday’s bell. For a fund that returned 93% over the prior twelve months, this was ... Broadcom Sneezed and COPJ Investors Lost 11% In A Day And Learned That Copper’s...
If you owned Sprott Junior Copper Miners ETF (NASDAQ:COPJ) on Friday morning, you watched it open near $45.37 and close at $40.37, an 11% single-day tumble on June 5, 2026. A $10,000 stake at Thursday’s close became roughly $8,900 by Friday’s bell. For a fund that returned 93% over the prior twelve months, this was ... Broadcom Sneezed and COPJ Investors Lost 11% In A Day And Learned That Copper’s AI Story Has a Pause Button
Walter Cicchetti/iStock Editorial via Getty Images By Shannon L. Saccocia and Joe Amato The SpaceX ( SPCX ) IPO is without precedent in scale and structure. Its implications for markets, indices and portfolios extend well beyond the deal itself. A pipeline of mega-cap private companies is headed toward public markets, potentially reshaping the equity landscape when they arrive. SpaceX, Elon Musk's...
Walter Cicchetti/iStock Editorial via Getty Images By Shannon L. Saccocia and Joe Amato The SpaceX ( SPCX ) IPO is without precedent in scale and structure. Its implications for markets, indices and portfolios extend well beyond the deal itself. A pipeline of mega-cap private companies is headed toward public markets, potentially reshaping the equity landscape when they arrive. SpaceX, Elon Musk's aerospace, satellite communications and artificial intelligence (AI) company, is the first. It has a target IPO valuation of around $1.8 trillion, raising capital of up to $75 billion in the process. To put that in context: oil major Saudi Aramco’s ( ARMCO ) 2019 offering, the largest in history, raised $25.6 billion on a $1.7 trillion valuation, while Alibaba’s ( BABA ) 2014 deal, long the benchmark for technology IPOs, raised $21.8 billion and was valued at $170 billion. The SpaceX IPO is 10 times larger than the latter, and we expect strong retail demand for the shares. But it will not be the only high-value public offering this year: Anthropic ( ANTHRO ) recently filed with the U.S. Securities and Exchange Commission, and we expect OpenAI ( OPENAI ) to be coming soon as well. Anthropic and OpenAI raised capital in private offerings earlier this year at valuations approaching $1 trillion. This wave of listings will dramatically reshape the indices most investors track and further test the depth of investor demand for mega-cap tech following the record $85 billion equity offering last week from Alphabet, Google’s parent. Three Businesses, One Valuation Following its February 2026 merger with xAI, SpaceX is effectively three businesses: a launch operation anchored by its Falcon 9 rocket—which commands approximately 90% of global commercial launch market share—Starlink, its satellite internet company targeting about 100 million subscribers and $140 billion in revenue by 2030 (according to the IPO underwriters), and xAI, its artificial intelligence subsidiary. By 2030, xAI ...
Honeywell International ( HON ) reaffirmed its full-year 2026 financial guidance on Monday and outlined preliminary expectations for the company that will remain after the planned June 29 spin-off of its aerospace division. Shares were little changed in premarket trading, erasing an earlier decline. The industrial conglomerate said it continues to expect 2026 sales of $38.8 billion to $39.8 billio...
Honeywell International ( HON ) reaffirmed its full-year 2026 financial guidance on Monday and outlined preliminary expectations for the company that will remain after the planned June 29 spin-off of its aerospace division. Shares were little changed in premarket trading, erasing an earlier decline. The industrial conglomerate said it continues to expect 2026 sales of $38.8 billion to $39.8 billion, with organic revenue growth of 3% to 6%. Adjusted earnings per share are projected at $10.35 to $10.65, representing growth of 6% to 9% from the prior year. The company also maintained its forecast for free cash flow of $5.3 billion to $5.6 billion. Honeywell disclosed the updated outlook ahead of an investor conference call and its Investor Day scheduled for June 11. The aerospace separation is part of a broader restructuring effort that will leave the remaining company operating under the name Honeywell Technologies. Investors have been closely watching the transaction as industrial companies increasingly pursue breakups to simplify operations and unlock shareholder value. The guidance provides an early look at the earnings power and cash generation prospects of the post-spin business. For Honeywell Technologies, the company forecast 2026 sales of $19.9 billion to $20.2 billion and organic growth of 2% to 3%. Segment margins are expected to range from 19.8% to 20.3%, reflecting expansion of 220 to 270 basis points from 2025 levels. Adjusted earnings per share for the remaining company are projected at $3.95 to $4.15, representing growth of 22% to 28%, while free cash flow is expected to be about $2.0 billion. The outlook excludes results from the aerospace business and incorporates the planned sales of Productivity Solutions and Services and Warehouse and Workflow Solutions, both of which Honeywell expects to complete by the fourth quarter. The forecast also includes estimated contributions from the acquisition of Johnson Matthey's Catalyst Technologies business, which...
Duluth Holdings ( DLTH ) reported sales fell 4.1% year over year to $98.6M in Q1. Direct-to-consumer sales were down 8.7% to $57.1M due to declines in web traffic and web conversion due to reduced promotional activity partially offset by higher average order values. Meanwhile, retail store sales increased by 3.3% to $41.5M, driven by higher average order values in comparable stores, coupled with t...
Duluth Holdings ( DLTH ) reported sales fell 4.1% year over year to $98.6M in Q1. Direct-to-consumer sales were down 8.7% to $57.1M due to declines in web traffic and web conversion due to reduced promotional activity partially offset by higher average order values. Meanwhile, retail store sales increased by 3.3% to $41.5M, driven by higher average order values in comparable stores, coupled with two new stores opened in the third quarter of 2025. CEO Stephanie Pugliese said customers are responding positively to core products, seasonal prints and patterns, and the newest marketing campaign. The retailer saw gross margin expand by 540 basis points to 57.4% of sales during the quarter. The increase in gross margin rate was primarily driven by an increase in average unit retail prices from reduced promotional activity, coupled with an improvement in product costs from the direct-to-factory sourcing initiative, partially offset by tariff costs. Non-GAAP EPS was reported at -$0.20 vs. -$0.39 consensus and -$0.44 a year ago. On the balance sheet, Duluth Holdings ( DLTH ) ended the quarter with $6.1M of cash and cash equivalents, $62.3M of net working capital, and $6.0M in outstanding debt on the $100.0M asset-based lending facility, resulting in approximately $100M of net liquidity. Looking ahead, Duluth Holdings ( DLTH ) sees FY26 sales landing in a range of $540M to $560M (midpoint $550M) vs. the consensus estimate of $555.6M. "O ur focus remains on delivering the core, high-quality, solution-based products that resonate most with our customers and creating an exceptional experience," stated Pugliese. Shares of Duluth Holdings ( DLTH ) were up 1.8% in premarket trading to $3.38 vs. the 52-week range of $1.82 to $4.66. More on Duluth Holdings Duluth Holdings Still Needs To Prove Itself Duluth Holdings: Showing Signs Of Stabilization Duluth Holdings Inc. (DLTH) Q4 2025 Earnings Call Transcript Duluth Holdings Non-GAAP EPS of -$0.20 beats by $0.19, revenue of $98.59M beats...